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.Abstract The stereoselective hydrolysis of esmolol in whole blood and in its separated components
from rat, rabbit and human was investigated. Blood esterase activities were variable in different
species in the order of rat4rabbit4human. Rat plasma showed the high esterase activity and had
no stereoselectivity to enantiomers. Rabbit red blood cell (RBC) membrane, RBC cytosol and
plasma all hydrolyzed esmolol but with different esterase activity, whereas the hydrolysis in RBC
membrane and cytosol showed signiﬁcant stereoselectivity towards R-(þ)-esmolol. Esterase in RBC
cytosol from human blood mainly contributed to the esmolol hydrolysis, which was demonstrated
with no stereoselctivity. Esterase in human plasma showed a low activity, but a remarkable
stereoselectivity with R-(þ)-esmolol. In addition, the protein concentration affected the hydrolysis
behavior of esmolol in RBC suspension. Protein binding of esmolol enantiomers in human plasma,
human serum albumin (HSA) and a1-acid glycoprotein (AGP) revealed that there was a signiﬁcant
difference in bound fractions between two enantiomers, especially for AGP. Our results indicated
that the stereoselective protein binding might play a role in the different hydrolysis rates of esmolol
enantiomers in human plasma.
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1. Introduction
Esmolol, methyl 3-{4-[2-hydroxy-3-(isopropylamino)propox-
y]phenyl}propionate hydrochloride, is an ultra-short-acting
b-adrenergic receptor antagonist for the rapid control of heart
rate in patients with atrial ﬁbrillation and also for the
treatment of tachycardia especially with hypertension during
surgery and in the postoperative period when indicated [1,2].
Esmolol is usually used as a racemic mixture of two enatio-
mers. In general, like most b-adrenergic blocking agents [3–5],
S-()-esmolol exhibits blocking effects whereas R-(þ)-esmolol
is inactive [6].
Analysis of species-dependent hydrolysis and protein binding of esmolol enantiomers 221Similar to many ester-containing drugs [7–9], esmolol is
rapidly metabolized by hydrolysis of the ester linkage to an
acid metabolite, 3-{4-[2-hydroxy-3-(isopropylamino)propoxy]-
phenyl} propionic acid, which has low potency as a b-
adrenergic receptor antagonist. In humans, hydrolysis of
esmolol is mediated mainly by an esterase in the cytosol of
red blood cells and the half-life of esmolol is approximately
9 min in vivo [10]. Species differences of the esterase activity
and stereoselectivity for hydrolysis of esmolol were observed
[10,11]. In whole blood, esmolol esterase activity was in the
order of guinea pigs4rats4rabbits4dogs4rhesus monkeys4
humans. S-()-esmolol is hydrolyzed faster than the R-(þ)-
esmolol with dog and rat blood esterase whereas R-(þ)-esmolol
is hydrolyzed faster with rhesus monkeys, rabbit, and guinea pig
blood esterase. Human esterase did not show stereoselectivity
[10]. Inhibition experiments showed that an arylesterase in
human and dog blood mediated the hydrolysis of esmolol
while an aliphatic esterase mediated the hydrolysis of esmolol
in guinea pig and rat blood [11]. Temperature also affected the
metabolism of esmolol in vitro. Melendez et al. [12] reported a
temperature-dependent decrease in the degradation of esmolol.
The half-life for esmolol in human blood was 19.673.8 min
at 37 1C, 47710.1 min at 25 1C, 152746.6 min at 15 1C, and
226.7760.1 min at 4 1C. This study clearly showed marked
reduction of esmolol metabolism with hypothermia, which
possibly leads to persistent beta-adrenergic blockade following
the discontinuation of cardiopulmonary bypass (CPB). However,
few data are available describing the stereoselectivity of hydro-
lyzing esmolol in the separated components of whole blood, such
as plasma, red blood cell (RBC), RBC cytosol, RBC membrane.
The present study focused on investigating the stereoselec-
tive hydrolysis of esmolol enantiomers in whole blood and in
its separated components from several species including
human in vitro. Furthermore, the stereoselective protein
binding of esmolol enantiomer was determined in human
plasma proteins, human serum albumin (HSA) and a-acid
glycoprotein (AGP), which play an important role in the
protein binding of many chiral drugs [13,14], therefore for the
ﬁrst time to explain the underlying reason for the different
hydrolyzing behavior of two enantiomers.2. Experimental
2.1. Reagents and apparatus
All solvents used were HPLC grade and all chemicals were
analytical grade. Esmolol hydrochloride (purity499.5%) was
kindly provided by Zhan Wang Chemical Pharmaceutical
Company (Huzhou, Zhejiang, China). 3-{4-[2-hydroxy-3-(iso-
propylamino)propoxy]phenyl}propionic acid (purity499.5%)
was synthesized by our laboratory according to the method
provided by Zhan Wang Chemical Pharmaceutical Company.
2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl isothiocyanate (GITC),
the internal standard (I.S.) ()-S-propranolol, HSA and AGP
were purchased from Sigma (St. Louis, MO, USA). Triethyla-
mine (TEA) was obtained from Shanghai Chemical Reagent
Plant (Shanghai, China).
The HPLC system consisted of an LC-10ATvp pump, a
manual injector with a 20 mL ﬁxed loop and an SPD-10Avp
UV–Vis detector (Shimadzu, Japan). The separation was
performed on a 5 mm reversed-phase Aglient Zorbax C18column (250 mm 4.6 mm I.D.), equipped with a C18 guard
column (10 mm 5 mm I.D.) at ambient temperature. The
mobile phase consisted of a mixture of acetonitrile/0.02 M
phosphate buffer (pH 4.5) (55:45, v/v) and was delivered at a
ﬂow rate of 0.75 mL/min. Eluted peaks were detected at
224 nm.
2.2. Collection of whole blood and its separated components
Whole blood was taken from Sprague-Dawley rats, New
Zealand rabbits (Laboratory Animal Center of Zhejiang
University, Hangzhou, China), and ﬁve healthy volunteers
aged 20–30 years, who took no medication for a week before
blood sampling. (This study was approved by the Ethics
Committee of Zhejiang University) The blood samples, col-
lected in heparinized tubes were centrifuged at 4 1C at 1800g
for 10 min to separate the plasma from the blood cells. The
resultant blood cells were washed for ﬁve times with an equal
volume of isotonic saline (pH 7.4) and centrifuged at 1800g for
5 min. The supernatant, including the white blood cells and
the platelets seen at the top of the RBC, was discarded, and
the RBC was suspended in adequate volumes of isotonic saline
or isotonic saline containing 600 mM HSA and 24 mM AGP to
obtain the same haematocrit values as the blood samples. The
RBC was further separated into the membrane and cytosol,
according to the previously reported method [15]. In brief, the
RBC suspension was diluted in a 10-fold volume of 0.005 M
phosphate buffer (pH 7.4) and centrifuged at 20,000g for
30 min at 4 1C to prepare the cytosol. The membrane pre-
cipitate was then washed for three times with a 10-fold volume
of isotonic saline, and suspended in the buffer to make it equal
volume with the original blood samples.
2.3. Hydrolysis study
Blood, plasma, RBC suspended in isotonic saline or isotonic
saline containing 600 mM HSA and 24 mM AGP, cytosol and
membrane suspended in phosphate buffer were pre-incubated
for 10 min at 37 1C. The incubation volume was 0.7 mL in all
experiments. Esmolol enantiomers were added to incubation
solution to give an initial concentration of 4 mg/mL. Incuba-
tion was performed at 37 1C. At different time intervals,
0.5 mL of samples were taken from the shaking water bath
and immediately mixed with 250 mL of 6% perchloric acid,
which immediately stopped the hydrolysis of esmolol. Then
the samples were stored at 20 1C until analysis.
2.4. Analytical methods
A RP-HPLC method was used to analyze the concentrations
of the enantiomers of esmolol and its metabolites according to
a method previously described [16–18]. Brieﬂy, the samples
prepared were placed on ice, and the internal standard was
immediately added. After centrifugation at 4 1C at 5000g for
10 min to precipitate proteins, the clear supernatant was
transferred to a clean tube and mixed with 100 mL of 1.0 M
sodium hydroxide and 1.5 mL of 0.02 M sodium phosphate
buffer (pH 7.0). The mixture was applied to LC-18 SPE
column (1.0 mL tube, Supelco Park, Bellefonte, PA, USA).
The sample solution was allowed to run through by gravity
and the cartridge was washed with 1.0 mL water. Excess of water
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about 30 min. The analytes were eluted from the cartridge with
3 mL of acetonitrile containing 1% glacial acetic acid. The eluent
was evaporated to dryness under a gentle stream of air. Then
70 mL of GITC (1.02 mg/mL in acetonitrile) and 5 mL of TEA
(1.25% in acetonitrile) were then added to the dried residue. The
reaction was made at ambient temperature for 20 min. After
chiral derivatization was completed, the reaction mixture was
evaporated to dryness under a gentle stream of air and the
residue was reconstituted with 100 mL of mobile phase. Finally,
an aliquot of 20 mL of the resulting solution was injected into the
HPLC system.2.5. Protein binding study
2.5.1. Nonspeciﬁc adsorption of esmolol enantiomers
to ultraﬁlter
Esmolol enantiomers were added to 0.7 mL Sorensen phos-
phate buffer, which had been pre-incubated for 10 min at
37 1C. After vertically mixing, 0.5 mL phosphate buffer was
taken into the Amicon centrifree micropartition systems ﬁtted
with the ﬁlter membrane with molecular weight cut-off value
of 30,000, and centrifuged at 2000g for 5 min at 37 1C.
Approximately 150 mL of the ultraﬁltrate was collected, then
the ultraﬁltrate and the phosphate buffer without ultraﬁltra-
tion were analyzed by HPLC without derivatization according
to the method previously described in Section 2.4.
Adsorption rate of the ultraﬁlter was calculated according
to the following equation:
P%¼ 1Aultrafilter=APBS
where Aultraﬁlter is the peak area of esmolol enantiomers in the
ultraﬁlter and APBS is the peak area of esmolol enantiomers in
the phosphate buffer.Table 1 The stereoselective hydrolysis of esmolol enan-
tiomers in while blood and in its separated components
from rat, rabbit and human (mean7SD, n¼5).
Matrix Hydrolysis activity (pmol/min/mL
blood)
S-()-esmolol R-(þ)-esmolol
Rat
Whole blood 119,606738,116 117,889737,512
Plasma 153,312741,235 148,285740,589
RBC 307.96712.31 298.58713.89
RBC cytosol 98.2179.25 93.1078.36
RBC membrane 105.62710.61 106.32713.65
Rabbit
Whole blood 783.12780.32 1310.117124.53
Plasma 284.74731.20 278.72728.012.5.2. Protein binding study with human plasma,
HSA and AGP
Esmolol enantiomers were added to 0.7 mL the human plasma or
600 mM HSA or 24 mM AGP solutions, which were prepared
with Sorensen phosphate buffer. To achieve equilibrium between
the drugs and proteins, the spiked protein samples containing
esmolol were incubated at 37 1C for 15 min. An aliquot of the
protein samples (0.5 mL) was used for the determination of the
total concentration of the enantiomers, while the remainder was
transferred to Amicon centrifree micropartition systems. The
samples mixed with human plasma, HSA and AGP were
centrifuged at 37 1C at 9000g for 15 min, 9000g for 5 min and
3000g for 5 min, respectively. Approximately 150 mL of the
ultraﬁltrate was collected, then the ultraﬁltrate and the phosphate
buffer without ultraﬁltration were analyzed by HPLC method.
RBC 408.28748.49 863.26790.47
RBC cytosol 118.1178.27 180.78711.75
RBC membrane 235.62716.79 397.13730.33
Human
Whole blood 109.9779.78 129.62710.25
Plasma 16.8771.35 31.2372.42
RBC 106.97710.16 109.69711.21
RBC cytosol 85.8279.45 82.5078.78
RBC membrane 7.7570.35 8.1570.41
RBC with HSA
and AGP
92.5079.45 101.4278.782.6. Data analysis
The enzyme activities for hydrolysis of esmolol enantiomer in
whole blood and its components were assumed to be the initial
slopes of the linear regression lines of plots of the production
of acid metabolite enantiomers vs. time. The activities were
corrected for dilution and expressed as the rate of the
metabolite generation in a unit time per equivalent volume
of whole blood.The in vitro half- lives of esmolol enantiomers (t1/2) were
determined by equation:
t1=2 ¼ ln2=k
where k is the hydrolysis rate constant, which was calculated
by linear regression analysis of log-transformed plasma con-
centrations of the enantiomers of esmolol vs. time.
The percentage bound was calculated using the following
equation:
The percentage bound¼ ½1ðCu=CtÞð1þ P%Þ  100%
where Cu and Ct are the unbound concentration and the total
concentration of the enantiomer of esmolol, and P% is the
nonspeciﬁc adsorbtion rate of the ultraﬁlter.
The drug–protein interactions are analyzed assuming that
the drug is bound to m class of identical independent binding
sites. The fraction r of bound drug molecules per protein
molecule is given by:
r¼
Xm
i ¼ 1
niKiCf
1þ KiCf
where Cf is the concentration of free drugs, ni is the number of
sites of class i and Ki is the corresponding association
constant.3. Results and discussion
3.1. Hydrolysis of esmolol in whole blood
The stereoselective hydrolysis of racemic esmolol is summarized
in Table 1. The in vitro hydrolysis of esmolol in blood was rapid
and stereoselective, although the hydrolysis rate and
Table 3 The nonspeciﬁc adsorption of esmolol with
ultraﬁlter (n¼3).
Spiked amount
(mg/mL)
APBS Aultraﬁltrate P (%) P (%)
0.5 12,063 11,582 3.81 2.80
3 71,873 70,551 1.84
15 358,945 349,038 2.76
50
60
S-(-)-esmolol
R-(+)-esmolol
n 
(%
)
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which was probably due to a species variation in the expression
of the esterase in the blood. In this study, the order of activity for
hydrolyzing esmolol was rat4rabbit4humans. And the esterase
activity in rat whole blood was approximately 100 and 1000
times higher than that in rabbit and human whole blood,
respectively. The high esterase activity in rat was consistent with
previous observations on other ester containing compounds,
such as clevidipine [19], remifentanil [20] and isocarbacyclin
methyl ester (TEI-9090) [21]. The hydrolysis of esmolol was
stereoselective with the esterases from rabbit and human blood,
R-(þ)-enantiomer faster than S-()-enantiomer, whereas no
stereoselectivity with the esterases from rat blood was observed.
The mean R-(þ)/S-()-esmolol ratio in rabbit and human whole
blood was 1.67 and 1.18, respectively.
3.2. Hydrolysis of esmolol in the separated components
of whole blood
The hydrolysis activities in separated components of whole
blood from rats, rabbits and humans were measured following
addition of 4 mg/mL of racemic esmolol (Table 1). In rats,
plasma esterases mainly contributed to esmolol hydrolysis and
showed no selectivity towards two enantiomers. Quon et al.
[11] reported a S-()-preferential hydrolysis in rat plasma, but
in our experiments, the enantioselectivity disappeared. This
difference might result from the individual variation.
In contrast to the rat blood, the hydrolysis activity in the
rabbit blood was involved in all the RBC cytosol, RBC
membrane and plasma. RBC membrane activity was similar
with plasma activity and about 2 times higher than RBC
cytosol activity. However, the stereoselective hydrolysis of
esmolol was found only in RBC cytosol and membrane, which
showed signiﬁcant stereoselectivity toward S-()-esmolol. The
mean R-(þ)/S-()-esmolol ratio in RBC cytosol and mem-
brane was 1.53 and 1.68, respectively. These data suggested
that the hydrolysis of esmolol in RBC cytosol and membrane
might be catalyzed by different esterases.
The hydrolysis of esmolol in human blood was largely
mediated by esterase in RBC cytosol and did not show any
stereoselectivity, which was also previously reported by Quon
et al. [11]. Human plasma esterase exhibited a low activity but
a remarkable stereoselectivity with the R-(þ)/S-()-esmolol
ratio of 1.85.
Although the in vitro half-life of esmolol in RBC was lower
than that in human whole blood, the addition of plasma proteins
to human RBC suspension slightly elongated the half-life of
esmolol and promoted the stereoselectivity of hydrolysis
(Table 2). The mean half-life of S-()-esmolol in human RBC
suspension containing HSA and AGP was 29.91 min, and theTable 2 Half-lives of esmolol enantionmers in RBC
suspension with or without HSA and AGP (mean7SD,
n¼3).
Matrix Half-lives (min)
S-()-esmolol R-(þ)-esmolol
RBC 24.2771.17 23.8871.33
RBC with HSA and AGP 29.9171.39 26.0771.06corresponding half-life of R-(þ)-esmolol was 26.07 min. Similar
ﬁndings with aspirin [22], clevidipine and TEI-9090 indicated that
protein molecules protect the drugs from RBC esterases in human
whole blood. This machinery could also be applied to esmolol.
3.3. Protein binding of esmolol
3.3.1. Nonspeciﬁc adsorption of esmolol enantiomers
to ultraﬁlter
The nonspeciﬁc adsorption of esmolol enantiomers at different
concentrations to ultraﬁlter is shown in Table 3. All non-
speciﬁc adsorption rates are less than 3%, indicating that the
ultraﬁlter can be used for studying protein binding.
3.3.2. Esmolol enantiomers binding with human plasma proteins
The binding of esmolol enantiomers to plasma proteins using
ultraﬁltration method is given in Fig. 1. The percentages of
protein binding of esmolol in the concentration range between
0.25 and 15 mg/mL were 31.06–53.04% for S-()-esmolol and
28.41–42.12% for R-(þ)-esmolol, and presented a concentra-
tion-dependent manner. Furthermore, the protein binding
rates of S-()-esmolol and R-(þ)-esmolol showed signiﬁcant
difference (Po0.01), and the binding of human plasma
proteins with esmolol enantiomers showed stereoselectivity
toward S-()-esmolol.
3.3.3. Esmolol enantiomers binding with HSA
The binding of esmolol enantiomers to HSA is given in
Fig. 2(A). The percentages of protein binding of esmolol in
the concentration range between 0.25 and 15 mg/mL were
12.45–17.45% for S-()-esmolol and 12.51–15.89% for R-(þ)-
esmolol, and did not show any signiﬁcant difference.0 5 10 15
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B
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Figure 1 The binding of esmolol enantiomers to plasma proteins.
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Figure 2 The binding of esmolol enantiomers to HSA. (A) The
bound fraction of esmolol enantiomers vs. concentration in HSA;
(B) the bound concentration vs. unbound concentration of
esmolol enantiomers in HSA.
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Figure 3 The binding of esmolol enantiomers to AGP. (A) The
bound fraction of esmolol enantiomers vs. concentration in AGP;
(B) scatchard plots for the binding of esmolol enantiomers in AGP.
Table 4 Binding parameters of esmolol enantiomers
in AGP.
Binding parameters S-()-esmolol R-(þ)-esmolol
N 0.45 0.44
K (L/mol) 6.31 104 4.33 104
Y.-H. Tang et al.224As shown in Fig. 2(B), the binding of esmolol enantiomers to
HSA was non-speciﬁc, and the concentration of free esmolol
and bound esmolol was positively correlated (r40.99). There-
fore the binding activity (nK) of S-()-esmolol and R-(þ)-
esmolol was 241 and 237 L/mol, respectively, according to
Henry’s isotherm equation: Cb¼nKPtCf, where Pt is the
concentration of protein and Cb is the concentration of
bound drugs.
3.3.4. Esmolol enantiomers binding with AGP
The binding of esmolol enantiomers to AGP is given in Fig. 3(A).
The percentages of protein binding of esmolol in the concentra-
tion range between 0.25 and 15 mg/mL were 13.45–33.45% for
S-()-esmolol and 11.55–25.78% for R-(þ)-esmolol, higher than
that to HSA. As shown in Fig. 3(B), esmolol enantiomers bound
to a single site of AGP, and m¼1. The binding parameters of
esmolol enantiomers to AGP are presented in Table 4 according
to the following equation: r¼nKCf/(1þKCf). The ratio of binding
activity was 1.5, indicating that the binding of esmolol with AGP
had stereoselectivity toward S-()-esmolol.
Therefore, the results showed that the binding of esmolol
enantiomers to human plasma was stereoselective toward
S-()-esmolol, which was consistent with the previously
reported results by dialysis [17]. The underlying reason for
this selectivity may be the signiﬁcantly stereoselective bindingof esmolol enantiomers to AGP, not to HSA. The stereo-
selective binding might interpret the difference of the in vitro
hydrolysis of esmolol enantiomer in human blood. Further-
more, the stereoselectivity of hydrolyzing esmolol in human
plasma is more signiﬁcant than that in whole blood and RBC
suspension containing HSA and AGP. This discrepancy might
be caused by the relative low protein concentration in whole
blood or the different esterase in human plasma.4. Conclusion
In the present study, the stereoselective hydrolysis of esmolol
in whole blood and in its separated components including
RBC membrane, RBC cytosol and plasma of rat, rabbit and
human was investigated. Blood esterase activities were in the
order of rat4rabbit4human, and species-dependent in sepa-
rated components of blood. The esmolol hydrolysis in human
Analysis of species-dependent hydrolysis and protein binding of esmolol enantiomers 225blood are mainly catalyzed by the esterase in RBC cytosol and
without stereoselctivity. And the addition of protein affected
the hydrolysis rate of esmolol in RBC suspension. Esterase in
human plasma showed a low activity, but a remarkable
stereoselectivity toward R-(þ)-esmolol. Therefore, the protein
binding study was performed to determine which protein
contributed to this phenomenon. The binding of esmolol
enantiomers to HSA and AGP showed that the bound
fractions of two enantiomers was signiﬁcantly different,
especially for AGP, which might be one of the reasons for
the different hydrolysis rates of esmolol enantiomers in human
plasma in vitro.
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